Literature DB >> 20675779

Strength and weakness of the new TNM classification for lung cancer.

R Rami-Porta, P Goldstraw.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20675779     DOI： 10.1183/09031936.00016210

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

Review 1.  The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications.

Authors:  Wanyin Lim; Carole A Ridge; Andrew G Nicholson; Saeed Mirsadraee
Journal:  Quant Imaging Med Surg       Date:  2018-08

2.  Getting familiar with the forthcoming eighth edition of TNM classification of lung cancer: from the T to N and M descriptors.

Authors:  Jad El Masri; Shengxiang Ren; Jun Zhang
Journal:  Ann Transl Med       Date:  2016-02

3.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

4.  Decreased expression of EFCC1 and its prognostic value in lung adenocarcinoma.

Authors:  Liang Xia; Yunke Zhu; Chuanfen Zhang; Senyi Deng; Yulan Deng; Zhenyu Yang; Jiandong Mei; Lunxu Liu
Journal:  Ann Transl Med       Date:  2019-11

5.  Prognostic Signature, Immune Features, and Therapeutic Responses of a Novel Ubiquitination-Related Gene Signature in Lung Adenocarcinoma.

Authors:  Muge Xu; Jiening Gong
Journal:  J Oncol       Date:  2022-08-16       Impact factor: 4.501

6.  Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer.

Authors:  Yu-Ning Liu; Xiao-Bing Wang; Teng Wang; Chao Zhang; Kun-Peng Zhang; Xiu-Yi Zhi; Wei Zhang; Ke-Lin Sun
Journal:  Chin Med J (Engl)       Date:  2016-09-05       Impact factor: 2.628

7.  [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis 
and Prognosis of Stage I-II Non-small Cell Lung Cancer].

Authors:  Yuning Liu; Xiaobing Wang; Teng Wang; Chao Zhang; Kunpeng Zhang; Ruochuan Zang; Xiuyi Zhi; Wei Zhang; Kelin Sun
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-04-20

8.  Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.

Authors:  Karmen Stanic; Nina Turnsek; Martina Vrankar
Journal:  Radiol Oncol       Date:  2019-11-20       Impact factor: 2.991

9.  Serum tumour M2-pyruvate kinase as a biomarker for diagnosis and prognosis of early-stage non-small cell lung cancer.

Authors:  Chunhua Xu; Wei Liu; Li Li; Yuchao Wang; Qi Yuan
Journal:  J Cell Mol Med       Date:  2021-07-13       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.